Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Barrett's oesophagus--a pathologist's view.

J-F Fléjou1, M Svrcek

  • 1Service d'Anatomie Pathologique, Hôpital Saint-Antoine, AP-HP, Paris, France. jean-francois.flejou@sat.aphp.fr

Histopathology
|January 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy.

ESMO gastrointestinal oncology·2026
Same author

Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice.

Techniques in coloproctology·2024
Same author

Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma.

Clinics and research in hepatology and gastroenterology·2023
Same author

Magnifying chromoendoscopy with targeted biopsies of intramucosal signet cell adenocarcinomas in a CDH1 pathogenic variant asymptomatic carrier.

Clinics and research in hepatology and gastroenterology·2022
Same journal

TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma.

Histopathology·2026
Same journal

Malignant adenomyoepithelioma of the breast: seven cases illustrating morphological diversity and diagnostic challenges.

Histopathology·2026
Same journal

A CRX-positive RB1-deficient bone tumour with a retinoblastoma-like DNA methylation profile.

Histopathology·2026
Same journal

Perivascular epithelioid cell tumours of the genitourinary tract: clinicopathological features and molecular landscape.

Histopathology·2026
Same journal

Navigating diagnostic challenges in low-grade spindle cell lesions of the breast: a retrospective review.

Histopathology·2026
Same journal

Neoplastic transformation of sporadic gastric hyperplastic polyps: a systematic review and meta-analysis of risk factors and clinicopathological features.

Histopathology·2026
See all related articles

Barrett's oesophagus surveillance relies on biopsies to detect dysplasia, a subjective marker. Alternative biomarkers like DNA aneuploidy and p53 alterations show promise for improved diagnosis and patient management.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pathology

Background:

  • Barrett's oesophagus is a precancerous condition for oesophageal adenocarcinoma.
  • It is characterized by intestinal metaplasia in the lower oesophagus.
  • The significance of short segments of intestinal metaplasia is debated.

Purpose of the Study:

  • To review current surveillance methods for Barrett's oesophagus.
  • To discuss the limitations of dysplasia grading.
  • To explore alternative biomarkers and future diagnostic technologies.

Main Methods:

  • Review of current endoscopic and histological surveillance protocols.
  • Discussion of limitations in dysplasia assessment.
  • Evaluation of proposed alternative biomarkers (DNA aneuploidy, proliferation markers, p53).

Related Experiment Videos

Main Results:

  • Current surveillance relies on systematic biopsies for dysplasia detection.
  • Dysplasia grading faces challenges in sampling, reproducibility, and natural history interpretation.
  • DNA aneuploidy, proliferation markers, and p53 alterations show potential as adjunct biomarkers.

Conclusions:

  • Limitations in current dysplasia assessment necessitate exploration of alternative biomarkers.
  • Advancements in endoscopic techniques and potential for 'virtual biopsies' may improve diagnosis.
  • Pathologists play a role in evaluating new therapies for early neoplastic lesions in Barrett's oesophagus.